A Systematic Review of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Volume: 26, Issue: 3, Pages: S133 - S133
Published: Mar 1, 2020
Abstract
Introduction null Defibrotide (DF) is approved for adult and pediatric patients (pts) with hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) with renal or pulmonary dysfunction after hematopoietic cell transplantation (HCT) in the United States and Canada, and for severe hepatic VOD/SOS post-HCT in patients aged >1 month in the European Union. The recommended dose is 25 mg/kg/day given as a 2-hour intravenous (IV) infusion...
Paper Details
Title
A Systematic Review of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome
Published Date
Mar 1, 2020
Volume
26
Issue
3
Pages
S133 - S133
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.